Efficacy Of Dexmedetomidine As A Neuraxial Adjuvant For Elective Cesarean Sections: A Meta-Analysis Of Randomized Trials

Meijuan Yang,Luyang Wang,Hong Chen,Xinzhong Chen
2018-01-01
Abstract:Objective: To evaluate the efficacy and safety of dexmedetomidine as a neuraxial adjuvant for elective caesarean section. Methods: We searched the randomized controlled trials (RCTs) assessing the effect of dexmedetomidine as a neuraxial adjuvant in elective caesarean section in PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases. Results: 11 RCTs were included. Overall, compared with control intervention in patients with elective cesarean section, dexmedetomidine intervention could significantly improve the characteristics of the block, including onset of sensory block (MD: -1.31 minutes; 95% CI: -2.68 to -0.06; P < 0.1), onset of motor block (MD: -0.79 minutes; 95% CI: -1.13 to -0.46; P < 0.05), duration of the sensory block (MD: 64.30 minutes; 95% CI: 21.67 to 106.93; P < 0.05) and duration of the motor block (MD: 24.69 minutes; 95% CI: 8.67 to 44.31; P < 0.05). Additionally, when compared with control group dexmedetomidine could prolong time to rescue analgesia (SMD: 3.81; 95% CI: 2.92 to 4.70; P < 0.05) and reduce the fentanyl consumption (RR= 0.20, 95% CI: 0.10-0.38, P < 0.05). The incidence of shivering in the dexmedetomidine group was significantly lower than that in the control group (RR= 0.41, 95% CI: 0.29-0.58, P < 0.05). The incidences of nausea and vomiting, bradycardia, hypotension and pruritus were not different between the two groups. Conclusion: Dexmedetomidine as a neuraxial adjuvant can improve the characteristics of the block, prolong time to rescue analgesia, reduce fentanyl consumption, and decrease the incidence of shivering during elective cesarean section.
What problem does this paper attempt to address?